Results 81 to 90 of about 10,096 (205)

Radiogenomics: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 2, February 2026.
Radiogenomics links imaging phenotypes with genetic variations, offering potential for comprehensive understanding, cost‐effective diagnosis, and prognosis prediction to advance personalized medicine. However, its clinical application remains limited by several challenges.
Xinyu Zhang, Qingpei Lai, Jin Cao, Jerry Chi Fung Ching, Xinzhi Teng, Jiang Zhang, Shara Wee Yee Lee, Ge Ren, Jing Cai   +8 more
wiley   +1 more source

Molecular alterations in high‐grade neuroendocrine tumors of the small intestine

The Journal of Pathology, Volume 268, Issue 2, Page 215-226, February 2026.
Abstract High‐grade neuroendocrine tumors of the small intestine are separated into two groups: well‐differentiated neuroendocrine tumors (NETs, high‐grade) and poorly differentiated neuroendocrine carcinomas (NECs). They represent very rare entities, with few molecular data available, and are very challenging to treat.
Agathe Hercent, Julien Masliah‐Planchon, David Cohen, Remy Nicolle, Jean‐Yves Scoazec, Philippe Ruszniewski, Ivan Bièche, Louis de Mestier, Anne Couvelard, Jerome Cros   +9 more
wiley   +1 more source

Lack of correlation between MYCN expression and the Warburg effect in neuroblastoma cell lines

BMC Cancer, 2008
Background Many cancers preferentially meet their energy requirements through the glycolytic pathway rather than via the more efficient oxidative phosphorylation pathway. It is thought that this is an important adaptation in cancer malignancy.
Hatzinisiriou Irene, Cossins Luke R, Smith Danielle J, Haber Michelle, Nagley Phillip   +4 more
doaj   +1 more source

Functional Difference of MYC and MYCN in Combined Hepatocellular–Cholangiocarcinoma: Regulation of Differentiation by HNF1B

Cancer Science, Volume 117, Issue 2, Page 536-547, February 2026.
Combined hepatocellular–cholangiocarcinoma (cHCC‐CCA) is a tumor consisting of a mixture of hepatocellular carcinoma and intrahepatic cholangiocarcinoma (CCA) components, but the mechanisms of development are poorly understood. The activation of Myc may be implicated in the formation of cHCC‐CCA and this work demonstrates for the first time that Myc ...
Masanori Goto, Masahiro Yamamoto, Hiroki Tanaka, Yumiko Fujii, Kumi Takasawa, Yuki Kamikokura, Masayo Kamikokura, Nobuyuki Kobayashi, Taro Murakami, Yuji Nishikawa, Akira Takasawa   +10 more
wiley   +1 more source

The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells

EBioMedicine, 2015
Dysregulated expression of MYC family genes is a hallmark of many malignancies. Unfortunately, these proteins are not amenable to blockade by small molecules or protein-based therapeutic agents.
Long Gu, Peiguo Chu, Robert Lingeman, Heather McDaniel, Steven Kechichian, Robert J. Hickey, Zheng Liu, Yate-Ching Yuan, John A. Sandoval, Gregg B. Fields, Linda H. Malkas   +10 more
doaj   +1 more source

Genomic Profiling of Pediatric Solid Tumors With a Dual DNA/RNA Panel: JCCG‐TOP2 Study

Cancer Science, Volume 117, Issue 2, Page 522-535, February 2026.
In the JCCG‐TOP2 nationwide pediatric cancer genomic profiling study, 204 patients' tumors and peripheral blood from 50 institutions across Japan were successfully analyzed using a dual DNA/RNA panel. A total of 147 (72%) had potentially actionable findings, including diagnostic, prognostic, and therapeutic findings in 111 (54%), 61 (30%), and 64 (31%),
Kayoko Tao, Takako Yoshioka, Miho Kato, Kazuyuki Komatsu, Shinichi Tsujimoto, Kenichi Sakamoto, Kazuki Tanimura, Minako Sugiyama, Masahiro Sekiguchi, Yoshiko Nakano, Yoshihiro Otani, Yasushi Yatabe, Akihiko Yoshida, Hajime Okita, Junko Hirato, Kenichi Kohashi, Yukichi Tanaka, Shinji Kohsaka, Takashi Kubo, Kuniko Sunami, Makoto Hirata, Shuichi Tsutsumi, Hiroyuki Aburatani, Katsuyoshi Koh, Masahiro Hirayama, Shuhei Karakawa, Yukayo Terashita, Hiroyuki Fujisaki, Takeshi Yagi, Akihiro Yoneda, Shinji Mochizuki, Hiroyuki Shichino, Tatsuya Suzuki, Tetsuya Takimoto, Koichi Ichimura, Chitose Ogawa, Kimikazu Matsumoto, Hitoshi Ichikawa, Motohiro Kato   +38 more
wiley   +1 more source

Olfactory domain family protein 3 promotes the proliferation of MYCN-amplified neuroblastoma cell lines in vitro [PDF]

Jichu yixue yu linchuang
Objective To explore the function of olfactomedin domain family protein 3 (OLFM3) in neuroblastoma (NB). Methods The relationship between the expression of OLFM3 mRNA and v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog(MYCN ...
ZHANG Yao, ZHANG Xuan, JIA Anna, ZHAN Shijia, GUO Jinxin, CHANG Yan, GUO Yongli
doaj   +1 more source

A pilot study of chemoimmunotherapy in the postconsolidation setting for high‐risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group

Cancer, Volume 132, Issue 2, 15 January 2026.
Abstract Background Survival for patients with high‐risk neuroblastoma remains poor despite current‐era multimodality treatment that includes postconsolidation GD2‐directed immunotherapy. Given the promising responses in patients who receive dinutuximab‐based chemoimmunotherapy in the relapsed setting, the Children’s Oncology Group ANBL19P1 study ...
Ami V. Desai, Arlene Naranjo, Brian LaBarre, Lulu Chen, Kelly C. Goldsmith, Meaghan P. Granger, Lisa States, Sean G. Green, Mariel Trunzo, Wendy Fitzgerald, Steven G. DuBois, Rochelle Bagatell, Julie R. Park, Araz Marachelian   +13 more
wiley   +1 more source

MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines

Molecular Medicine Reports, 2018
Neuroblastoma derived from primitive sympathetic neural precursors is a common type of solid tumor in infants. MYCN proto‑oncogene bHLH transcription factor (MYCN) amplification and 1p36 deletion are important factors associated with the poor prognosis of neuroblastoma.
Altungöz, Oğuz, Aygun, Nevim
openaire   +4 more sources

Deregulated enhancer‐promoter communication in cancer through altered nuclear architecture

International Journal of Cancer, Volume 158, Issue 2, Page 409-422, 15 January 2026.
Abstract Enhancers are critical regulators of gene expression. Structural variations in cancer genomes can lead to enhancer hijacking, where oncogenes are activated by mistargeted enhancer activity. Novel enhancer‐promoter interactions may also arise through chromosomal rearrangements that create extrachromosomal DNA elements.
Isabelle Seufert, Claire Vargas, Sina Jasmin Wille, Karsten Rippe   +3 more
wiley   +1 more source